Olaparib Treatment Leads to Significant Survival Improvement in Patients with mCRPC
December 4th 2020A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.
Read More
Lower Risk of Death Observed With Enzalutamide in Patients with nmCRPC
December 4th 2020Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.
Read More
Understanding the Various Biomarker Settings for Metastatic Prostate Cancer
December 4th 2020In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.
Read More
Enzalutamide Shows PFS Benefit Across Subgroups of nmCRPC
December 3rd 2020Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Read More
Nadofaragene Firadenovec Demonstrates Continued Efficacy Across Subgroups in BCG-Unresponsive NMIBC
December 3rd 2020In a subgroup of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer, the novel intravesical gene-mediated therapy nadofaragene firadenovec maintained its efficacy, according to a poster shared during the 21st Annual Meeting of the Society of Urologic Oncology.
Read More
HIF-2α Inhibition Warranted for VHL-Associated Clear Cell Renal Cell Carcinoma
December 3rd 2020The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.
Read More
Incorporating Genomics into Lymphoma Classification Can Improve Care
November 21st 2020The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.
Read More
Big Data–Based Tools Support Cancer Clinical Decision-Making
November 20th 2020Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.
Read More
Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays
November 20th 2020Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.
Read More
Novel Assay Identifies Mutations, Fusions, Exon Skipping in Myeloid and Lymphoid Malignancies
November 20th 2020In an interview with Targeted Oncology during the Association for Molecular Pathology 2020 Annual Meeting, Rachel Sparks, MD, discussed the findings observed in hematologic malignancies with the use of a new RNA-based NGS assay.
Read More
Molecular Testing With Universal Method Comparable to Traditional Method in Hereditary Solid Tumors
November 17th 2020In an interview with Targeted Oncology during the 2020 Association for Molecular Pathology Annual Meeting, Ozge Ceyhan-Birsoy, PhD, discussed genetic testing methods for patients with hereditary predisposition and the molecular research underway at MSKCC to improve testing in this patient population.
Read More
Sequencing TP53 Mutations in Myeloid Neoplasms
November 17th 2020Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.
Read More
Inhibitors of MET, RET, and TRK Now Enjoy Standard of Care Status in Lung Cancer
November 9th 2020Alexander Drilon, MD, chief of Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York, discussed each of the recently approved agents used for the treatment of these tumors and presented a review of the data at the 15th Annual New York Lung Cancer Symposium.
Read More
COVID-19 Pandemic Creates Teachable Moment for Oncologists in Lung Cancer
November 9th 2020Many challenges have arisen as a result of the coronavirus 2019 pandemic, which is still impacting nations across the world. In the United States, oncologists have initiated research to provide wider understanding of the virus and the threat it poses to patients with lung cancer.
Read More
In an interview with Targeted Oncology, Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.
Read More
Kaelin Speaks to the Future of I/O, HIF-2α, CDK4/6 Inhibitors in VHL Disease–Associated RCC
November 7th 2020During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.
Read More
TMB Use as Immunotherapy Biomarker Fraught by Challenges, But Still Shows Potential
November 7th 2020Tumor mutational burden has been correlated with response to immunotherapy use in patients treated with immune checkpoint blockade. However, use of this biomarker has been challenged along the way with various criticisms of validity and routine use.
Read More
Safety, Tolerability Profile for Low-Dose Lenvatinib Is Similar to Standard Dose in RCC
November 7th 2020Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.
Read More
Immunotherapy Advances Treatment Landscape for Small Cell Lung Cancer
November 7th 2020An important milestone in the treatment landscape of extensive-stage small cell lung cancer has been trials of first-line chemoimmunotherapy. However, a study that requires better understanding of the methods and can be used to determine patients who are likely to experience durable benefits to therapy is currently concentrated.
Read More
Cost-Effective Option Best for Frontline Immunotherapy/TKI Combination in RCC
November 7th 2020Significant overall survival and progression-free survival benefits were observed with combination regimens containing immunotherapy in combination with a tyrosine kinase inhibitor, along with tolerable safety in patients with renal cell carcinoma to Suzanne Cole, MD, FACP noted, however, that the cost of these combination can dim the light on the advantages.
Read More